2021, Volume 27, Issue 4
THE IMPACT OF TIRZEPATIDE ON BODY MASS IN THE CLINICAL TRIALS SURMOUNT AND SURPASS
KINGA BRZDĘK1, MICHAŁ BRZDĘK1
-------------------------------------------------------------------------------------------------
1Collegium Medicum, Jan Kochanowski University in Kielce
Autor korenspondencyjny: KINGA BRZDĘK; Collegium Medicum, Jan Kochanowski University in Kielce; email: brzdekinga@gmail.com
Streszczenie
Introduction: Obesity and type 2 diabetes mellitus (T2DM) represent significant public health challenges globally, necessitating the development of effective therapeutic interventions. Tirzepatide (TZP), a novel dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist has emerged as a promising treatment modality for these conditions. The aim of this review is to provide an in-depth analysis of data from clinical trials conducted within the SURPASS and SURMOUNT programs, aiming to evaluate TZP's efficacy and safety in the management of obesity.
Methods: A literature review was conducted focusing on the full accessibility of sources. Databases such as PubMed, IEEE Xplore, ScienceDirect, and Google Scholar were searched. Searches were performed using keywords such as: "tirzepatide", "tirzepatide and ob esity", "GIP and GLP 1 receptor agonists", "tirzepatide and SURPASS", "tirzepatide and SURMOUNT".
Results: The comprehensive trials reveal evidence supporting benefits in weight reduction among patients with T2DM. Furthermore, the favorable safety profile observed in these trials enhances TZP's appeal as a therapeutic option for individuals with obesity and T2DM.
Discussion and conclusion: In conclusion, TZP emerges as a promising therapeutic agent with the potential to revolutionize the management of obesity and T2DM, offering comprehensive benefits beyond glycemic control and weight reduction. Despite these promising results, further research is warranted to elucidate TZP's impact on weight in populations with obesity without diabetes, as well as its long-term safety and economic implications. Such investigations will be crucial in forming personalized treatment strategies and optimizing the clinical utility of TZP in diverse patient populations.
Słowa kluczowe
Tirzepatide, obesity, SURMOUNT, SURPASS